Thursday, 23 October 2014
Last updated 1 hour ago
Sep 7 2007 | 1:17pm ET
After a rough August, hedge fund agitator Daniel Loeb might be inclined to write a venomous letter to himself.
His $3.7 billion Third Point Offshore Fund was down 8.3% in August, cutting its year-to-date returns to 6.8%.
According to the firm’s monthly investor letter, the fund’s “winners” last month include Lyondell Chemical, Alkermes Inc. and Ligand Pharmaceuticals, while “losers” included PDL BioPharma, Granite Construction and Leap Wireless. PDL BioPharma is the recipient of one of Loeb’s most recent trademark invective-filled missives.
The activist manager penned a letter to the company’s chairman, Patrick Gage, on Aug. 28 following PDL’s conference call demanding his resignation because Gage “gave the impression that repositioning the Company could be an alternative to selling the Company.” Loeb, who previously wanted the company to sell itself as a whole or in pieces, also cited the “lame duck” Gage’s emphasis on research and development strategies and “spotty” record at other public companies as catalysts for its demand for management change. New York-based Third Point currently owns a 9.7% stake in the company.
Sep 22 2014 | 4:15pm ET
"I tell people that everybody likes good news and so if you have good performance that’s wonderful,” explains Mike McKitish of Peddie School's endowment, “but it’s the people that want to talk about the bad news or where they drifted and how they came back and how they stayed to their discipline…” that he wants to hear from. Read more…
Most traders agree that proper risk management is the key to successful trading. However, many traders depend on the deeply flawed measure of standard deviation as a benchmark of risk. Here we put it ...